• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A(1)或A(3)腺苷受体通过不同机制诱导清醒家兔产生晚期心肌梗死预处理。

A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.

作者信息

Takano H, Bolli R, Black R G, Kodani E, Tang X L, Yang Z, Bhattacharya S, Auchampach J A

机构信息

Division of Cardiology, University of Louisville and Jewish Heart and Lung Institute, Louisville, KY, USA.

出版信息

Circ Res. 2001 Mar 16;88(5):520-8. doi: 10.1161/01.res.88.5.520.

DOI:10.1161/01.res.88.5.520
PMID:11249876
Abstract

We investigated whether activation of A(1) or A(3) adenosine receptors (ARs) induces late preconditioning (PC) against infarction in conscious rabbits using the selective AR agonists 2-chloro-N(6)-cyclopentyladenosine (CCPA) and N(6)-3-iodobenzyladenosine-5'-N-methylcarboxamide (IB-MECA). In vitro radioligand binding and cAMP assays demonstrated CCPA to be approximately 200- to 400-fold selective for the rabbit A(1)AR and IB-MECA to be approximately 20-fold selective for the rabbit A(3)AR. We observed that (1) pretreatment of rabbits 24 hours earlier with CCPA (100 microgram/kg IV bolus) or IB-MECA (100 or 300 microgram/kg) resulted in an approximately 35% to 40% reduction in the size of the infarct induced by 30 minutes of coronary artery occlusion and 72 hours of reperfusion compared with vehicle-treated rabbits, whereas pretreatment with the selective A(2A)AR agonist CGS 21680 (100 microgram/kg) had no effect; (2) the delayed cardioprotective effect of CCPA, but not that of IB-MECA, was completely blocked by coadministration of the highly selective A(1)AR antagonist N-0861; (3) inhibition of nitric oxide synthase (NOS) with N(omega)-nitro-L-arginine during the 30-minute occlusion abrogated the infarct-sparing action of CCPA but not that of IB-MECA; and (4) inhibition of ATP-sensitive potassium (K(ATP)) channels with sodium 5-hydroxydecanoate during the 30-minute occlusion blocked the cardioprotective effects of both CCPA and IB-MECA. Taken together, these results indicate that activation of either A(1)ARs or A(3)ARs (but not A(2A)ARs) elicits delayed protection against infarction in conscious rabbits and that both A(1)AR- and A(3)AR-induced cardioprotection involves opening of K(ATP) channels. However, A(1)AR-induced late PC uses an NOS-dependent pathway whereas A(3)AR-induced late PC is mediated by an NOS-independent pathway.

摘要

我们使用选择性腺苷受体(AR)激动剂2-氯-N(6)-环戊基腺苷(CCPA)和N(6)-3-碘苄基腺苷-5'-N-甲基羧酰胺(IB-MECA),研究了激活A(1)或A(3)腺苷受体是否能在清醒兔中诱导针对梗死的延迟预处理(PC)。体外放射性配体结合和环磷酸腺苷(cAMP)检测表明,CCPA对兔A(1)AR的选择性约为200至400倍,而IB-MECA对兔A(3)AR的选择性约为20倍。我们观察到:(1)与给予赋形剂处理的兔相比,提前24小时用CCPA(100微克/千克静脉推注)或IB-MECA(100或300微克/千克)预处理兔,可使冠状动脉闭塞30分钟和再灌注72小时后诱导的梗死面积减少约35%至40%,而用选择性A(2A)AR激动剂CGS 21680(100微克/千克)预处理则无效果;(2)同时给予高选择性A(1)AR拮抗剂N-0861可完全阻断CCPA的延迟心脏保护作用,但不影响IB-MECA的作用;(3)在30分钟闭塞期间用N(ω)-硝基-L-精氨酸抑制一氧化氮合酶(NOS)可消除CCPA的梗死面积缩小作用,但不影响IB-MECA的作用;(4)在30分钟闭塞期间用5-羟基癸酸钠抑制ATP敏感性钾(K(ATP))通道可阻断CCPA和IB-MECA的心脏保护作用。综上所述,这些结果表明,激活A(1)ARs或A(3)ARs(而非A(2A)ARs)可在清醒兔中引发针对梗死的延迟保护,且A(1)AR和A(3)AR诱导的心脏保护均涉及K(ATP)通道的开放。然而,A(1)AR诱导的延迟预处理使用的是依赖NOS的途径,而A(3)AR诱导的延迟预处理是由不依赖NOS的途径介导的。

相似文献

1
A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.A(1)或A(3)腺苷受体通过不同机制诱导清醒家兔产生晚期心肌梗死预处理。
Circ Res. 2001 Mar 16;88(5):520-8. doi: 10.1161/01.res.88.5.520.
2
Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors.环氧化酶-2不介导由腺苷A1或A3受体激活所诱导的延迟预处理。
Am J Physiol Heart Circ Physiol. 2001 Aug;281(2):H959-68. doi: 10.1152/ajpheart.2001.281.2.H959.
3
Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor.异丁基-甲基黄嘌呤-5'-N-乙基羧酰胺(IB-MECA)对清醒家兔心肌顿抑的保护作用并非由A1腺苷受体介导。
Basic Res Cardiol. 2001 Sep;96(5):487-96. doi: 10.1007/s003950170031.
4
Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits.用N6-(3-碘苄基)腺苷-5'-N-甲基脲苷选择性激活A3腺苷受体可保护清醒兔免受心肌顿抑和梗死,且不伴有血流动力学改变。
Circ Res. 1997 Jun;80(6):800-9. doi: 10.1161/01.res.80.6.800.
5
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.A3腺苷受体激动剂IB-MECA减轻犬心肌缺血再灌注损伤。
Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H607-13. doi: 10.1152/ajpheart.01001.2002. Epub 2003 Apr 10.
6
Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF- kappa B, iNOS and mitochondrial K(ATP) channel.心脏中腺苷A(3)受体激活引发的延迟预处理:核因子κB、诱导型一氧化氮合酶和线粒体ATP敏感性钾通道的作用
J Mol Cell Cardiol. 2002 Mar;34(3):263-77. doi: 10.1006/jmcc.2001.1510.
7
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.Cl-IB-MECA [2-氯-N6-(3-碘苄基)腺苷-5'-N-甲基甲酰胺] 通过激活A3腺苷受体减轻小鼠缺血/再灌注损伤。
J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10. doi: 10.1124/jpet.106.111351. Epub 2006 Sep 19.
8
Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.缺血预处理24小时后腺苷受体参与心肌保护的延迟期。
Circulation. 1994 Dec;90(6):2993-3000. doi: 10.1161/01.cir.90.6.2993.
9
Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits.一氧化氮合酶是清醒家兔心肌梗死延迟预处理的介质。
Circulation. 1998 Aug 4;98(5):441-9. doi: 10.1161/01.cir.98.5.441.
10
Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation.用N6-(3-氯苄基)-5'-N-甲基甲酰胺腺苷(CB-MECA)选择性激活腺苷A3受体可通过激活ATP敏感性钾通道提供心脏保护作用。
Cardiovasc Res. 1998 Oct;40(1):138-45. doi: 10.1016/s0008-6363(98)00112-6.

引用本文的文献

1
Synthetic Small-Molecule Ligands Targeted to Adenosine Receptors: Is There Potential Towards Ischemic Heart Disease?靶向腺苷受体的合成小分子配体:对缺血性心脏病有潜在作用吗?
Cells. 2025 Aug 7;14(15):1219. doi: 10.3390/cells14151219.
2
Nitric Oxide in Cardiac Surgery: A Review Article.心脏手术中的一氧化氮:一篇综述文章。
Biomedicines. 2023 Apr 3;11(4):1085. doi: 10.3390/biomedicines11041085.
3
Species dependence of A adenosine receptor pharmacology and function.A 腺苷受体药理学和功能的种属依赖性。
Purinergic Signal. 2023 Sep;19(3):523-550. doi: 10.1007/s11302-022-09910-1. Epub 2022 Dec 20.
4
The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury.心肌缺血再灌注损伤期间的缺氧-腺苷联系
Biomedicines. 2022 Aug 10;10(8):1939. doi: 10.3390/biomedicines10081939.
5
Effects of Heme Oxygenase-1 on c-Kit-Positive Cardiac Cells.血红素加氧酶-1 对 c-Kit 阳性心脏细胞的影响。
Int J Mol Sci. 2021 Dec 15;22(24):13448. doi: 10.3390/ijms222413448.
6
Effect of intravenous cell therapy in rats with old myocardial infarction.静脉细胞治疗对陈旧性心肌梗死大鼠的影响。
Mol Cell Biochem. 2022 Feb;477(2):431-444. doi: 10.1007/s11010-021-04283-2. Epub 2021 Nov 16.
7
Exercise-induced late preconditioning in mice is triggered by eNOS-dependent generation of nitric oxide and activation of PKCε and is mediated by increased iNOS activity.运动诱导的小鼠晚期预处理是由 eNOS 依赖性一氧化氮生成和 PKCε 的激活触发的,并且是由 iNOS 活性的增加介导的。
Int J Cardiol. 2021 Oct 1;340:68-78. doi: 10.1016/j.ijcard.2021.08.021. Epub 2021 Aug 14.
8
Echocardiography-guided percutaneous left ventricular intracavitary injection as a cell delivery approach in infarcted mice.超声心动图引导下经皮左心室内注射作为梗死小鼠细胞递送方法
Mol Cell Biochem. 2021 May;476(5):2135-2148. doi: 10.1007/s11010-021-04077-6. Epub 2021 Feb 5.
9
Infarct-Sparing Effect of Adenosine A2B Receptor Agonist Is Primarily Due to Its Action on Splenic Leukocytes Via a PI3K/Akt/IL-10 Pathway.腺苷A2B受体激动剂的梗死灶保留效应主要归因于其通过PI3K/Akt/IL-10信号通路对脾白细胞的作用。
J Surg Res. 2018 Dec;232:442-449. doi: 10.1016/j.jss.2018.06.042. Epub 2018 Jul 23.
10
New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types.细胞治疗的新范式:重复给药、静脉给药、免疫调节作用和新型细胞类型。
Circ Res. 2018 Jul 6;123(2):138-158. doi: 10.1161/CIRCRESAHA.118.313251.